Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt 13.92
SUPN's Cash-to-Debt is ranked higher than
63% of the 790 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.44 vs. SUPN: 13.92 )
Ranked among companies with meaningful Cash-to-Debt only.
SUPN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.19  Med: 2.84 Max: No Debt
Current: 13.92
Equity-to-Asset 0.61
SUPN's Equity-to-Asset is ranked lower than
54% of the 724 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. SUPN: 0.61 )
Ranked among companies with meaningful Equity-to-Asset only.
SUPN' s Equity-to-Asset Range Over the Past 10 Years
Min: -2.25  Med: 0.37 Max: 0.68
Current: 0.61
-2.25
0.68
Interest Coverage 8.52
SUPN's Interest Coverage is ranked lower than
74% of the 650 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 94.32 vs. SUPN: 8.52 )
Ranked among companies with meaningful Interest Coverage only.
SUPN' s Interest Coverage Range Over the Past 10 Years
Min: 1  Med: 4.37 Max: N/A
Current: 8.52
Piotroski F-Score: 6
Altman Z-Score: 8.06
Beneish M-Score: -1.49
WACC vs ROIC
19.82%
121.58%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 23.33
SUPN's Operating Margin % is ranked higher than
84% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.64 vs. SUPN: 23.33 )
Ranked among companies with meaningful Operating Margin % only.
SUPN' s Operating Margin % Range Over the Past 10 Years
Min: -37851.89  Med: -403.06 Max: 27.1
Current: 23.33
-37851.89
27.1
Net Margin % 42.66
SUPN's Net Margin % is ranked higher than
97% of the 737 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.21 vs. SUPN: 42.66 )
Ranked among companies with meaningful Net Margin % only.
SUPN' s Net Margin % Range Over the Past 10 Years
Min: -36285.85  Med: -194.23 Max: 6701.74
Current: 42.66
-36285.85
6701.74
ROE % 65.44
SUPN's ROE % is ranked higher than
98% of the 763 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.92 vs. SUPN: 65.44 )
Ranked among companies with meaningful ROE % only.
SUPN' s ROE % Range Over the Past 10 Years
Min: -202.72  Med: -85.51 Max: 65.44
Current: 65.44
-202.72
65.44
ROA % 39.75
SUPN's ROA % is ranked higher than
98% of the 798 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.58 vs. SUPN: 39.75 )
Ranked among companies with meaningful ROA % only.
SUPN' s ROA % Range Over the Past 10 Years
Min: -90.03  Med: -26.12 Max: 106.84
Current: 39.75
-90.03
106.84
ROC (Joel Greenblatt) % 1115.55
SUPN's ROC (Joel Greenblatt) % is ranked higher than
99% of the 785 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.01 vs. SUPN: 1115.55 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
SUPN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -4247.75  Med: -1920.51 Max: 1115.55
Current: 1115.55
-4247.75
1115.55
3-Year Revenue Growth Rate 223.70
SUPN's 3-Year Revenue Growth Rate is ranked higher than
99% of the 606 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.50 vs. SUPN: 223.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
SUPN' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 63.7 Max: 223.7
Current: 223.7
0
223.7
GuruFocus has detected 4 Warning Signs with Supernus Pharmaceuticals Inc $SUPN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» SUPN's 10-Y Financials

Financials (Next Earnings Date: 2017-02-28)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

SUPN Guru Trades in Q1 2016

Steven Cohen 944,746 sh (New)
Robert Bruce 224,581 sh (-11.78%)
Joel Greenblatt 17,552 sh (-48.08%)
Paul Tudor Jones 20,300 sh (-56.81%)
» More
Q2 2016

SUPN Guru Trades in Q2 2016

Robert Bruce 224,581 sh (unchged)
Paul Tudor Jones 14,500 sh (-28.57%)
Joel Greenblatt 12,455 sh (-29.04%)
Steven Cohen 35,600 sh (-96.23%)
» More
Q3 2016

SUPN Guru Trades in Q3 2016

Paul Tudor Jones 14,800 sh (+2.07%)
Steven Cohen Sold Out
Joel Greenblatt Sold Out
Robert Bruce 164,581 sh (-26.72%)
» More
Q4 2016

SUPN Guru Trades in Q4 2016

Steven Cohen 1,900 sh (New)
Paul Tudor Jones 27,577 sh (+86.33%)
Robert Bruce 164,581 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with SUPN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:NAS:MNTA, OTCPK:KHTRF, OTCPK:GNMLF, OTCPK:TWMJF, NAS:EGRX, NAS:SGYP, NAS:IPXL, OTCPK:EVTCY, NAS:DEPO, NAS:PCRX, NYSE:DPLO, OTCPK:NPPNY, NAS:AMPH, NYSE:LCI, NAS:HRTX, NAS:RDUS, OTCPK:APHQF, NAS:SCMP, NAS:FLXN, NAS:SCLN » details
Traded in other countries:S49.Germany,
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders.

Supernus Pharmaceuticals Inc was incorporated in Delaware on March 30, 2005. The Company is a specialty pharmaceutical company engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company markets two epilepsy products, Oxtellar XR and Trokendi XR, and has other proprietary product candidates in clinical development that address the psychiatry market. The Company is developing multiple product candidates in psychiatry to address the unmet medical needs and market opportunities in impulsive aggression across several areas including attention deficit hyperactivity disorder (ADHD), autism and bipolar disorder, and ADHD. The Company's neurology portfolio consists of Oxtellar XR and Trokendi XR. Oxtellar XR is indicated for adjunctive therapy of partial seizures in adults and in children 6 years to 17 years of age and Trokendi XR is indicated for initial monotherapy in patients 10 years of age and older with partial onset or primary generalized tonic-clonic seizures, and as adjunctive therapy in patients 6 years of age and older with partial onset or primary generalized tonic-clonic seizures or with seizures associated with Lennox-Gastaut syndrome. Its psychiatry product candidates include ADHD, SPN-810 (molindone hydrochloride) and SPN-812 (viloxazine hydrochloride). ADHD is a common CNS disorder characterized by developmentally inappropriate levels of inattention, hyperactivity, and impulsivity; and it develops SPN-810 (molindone hydrochloride) as a treatment for impulsive aggression in patients with ADHD in conjunction with standard ADHD treatment. The Company has a portfolio of drug development technologies consisting of platforms including Microtrol, Solutrol and EnSoTrol. It is utilized to create nine marketed products, including Trokendi XR and Oxtellar XR, as well as other product candidates SPN-810 and SPN-812. The Company markets its products in the United States through its specialty sales force. The Company is subject to regulation by FDA, federal and state government authorities. In addition to regulations in the United States, the Company is subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of the product candidates to the extent company choose to clinically evaluate or sell any products outside of the United States.

Ratios

vs
industry
vs
history
PE Ratio 16.05
SUPN's PE Ratio is ranked higher than
77% of the 568 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.40 vs. SUPN: 16.05 )
Ranked among companies with meaningful PE Ratio only.
SUPN' s PE Ratio Range Over the Past 10 Years
Min: 0.13  Med: 44.92 Max: 235.67
Current: 16.05
0.13
235.67
PE Ratio without NRI 16.05
SUPN's PE Ratio without NRI is ranked higher than
77% of the 543 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.84 vs. SUPN: 16.05 )
Ranked among companies with meaningful PE Ratio without NRI only.
SUPN' s PE Ratio without NRI Range Over the Past 10 Years
Min: 11.37  Med: 49.17 Max: 235.67
Current: 16.05
11.37
235.67
Price-to-Owner-Earnings 13.50
SUPN's Price-to-Owner-Earnings is ranked higher than
83% of the 300 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 34.72 vs. SUPN: 13.50 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
SUPN' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 9.56  Med: 33.47 Max: 171.05
Current: 13.5
9.56
171.05
PB Ratio 7.19
SUPN's PB Ratio is ranked lower than
82% of the 827 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.02 vs. SUPN: 7.19 )
Ranked among companies with meaningful PB Ratio only.
SUPN' s PB Ratio Range Over the Past 10 Years
Min: 3.23  Med: 7.37 Max: 18.53
Current: 7.19
3.23
18.53
PS Ratio 6.58
SUPN's PS Ratio is ranked lower than
72% of the 766 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.06 vs. SUPN: 6.58 )
Ranked among companies with meaningful PS Ratio only.
SUPN' s PS Ratio Range Over the Past 10 Years
Min: 3.75  Med: 6.97 Max: 103.29
Current: 6.58
3.75
103.29
Price-to-Free-Cash-Flow 21.83
SUPN's Price-to-Free-Cash-Flow is ranked higher than
50% of the 226 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 22.72 vs. SUPN: 21.83 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
SUPN' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 15.47  Med: 28.47 Max: 81.58
Current: 21.83
15.47
81.58
Price-to-Operating-Cash-Flow 21.04
SUPN's Price-to-Operating-Cash-Flow is ranked lower than
61% of the 295 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.98 vs. SUPN: 21.04 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
SUPN' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 14.92  Med: 26.49 Max: 75.75
Current: 21.04
14.92
75.75
EV-to-EBIT 25.15
SUPN's EV-to-EBIT is ranked lower than
63% of the 574 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.65 vs. SUPN: 25.15 )
Ranked among companies with meaningful EV-to-EBIT only.
SUPN' s EV-to-EBIT Range Over the Past 10 Years
Min: -71.5  Med: -2.1 Max: 96
Current: 25.15
-71.5
96
EV-to-EBITDA 24.18
SUPN's EV-to-EBITDA is ranked lower than
70% of the 600 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.72 vs. SUPN: 24.18 )
Ranked among companies with meaningful EV-to-EBITDA only.
SUPN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -89.2  Med: -2.1 Max: 88.7
Current: 24.18
-89.2
88.7
Current Ratio 1.93
SUPN's Current Ratio is ranked lower than
60% of the 726 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.49 vs. SUPN: 1.93 )
Ranked among companies with meaningful Current Ratio only.
SUPN' s Current Ratio Range Over the Past 10 Years
Min: 1.51  Med: 2.92 Max: 7.26
Current: 1.93
1.51
7.26
Quick Ratio 1.69
SUPN's Quick Ratio is ranked lower than
53% of the 725 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.84 vs. SUPN: 1.69 )
Ranked among companies with meaningful Quick Ratio only.
SUPN' s Quick Ratio Range Over the Past 10 Years
Min: 1.49  Med: 2.69 Max: 7.26
Current: 1.69
1.49
7.26
Days Inventory 492.01
SUPN's Days Inventory is ranked lower than
97% of the 687 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.19 vs. SUPN: 492.01 )
Ranked among companies with meaningful Days Inventory only.
SUPN' s Days Inventory Range Over the Past 10 Years
Min: 492.01  Med: 652.7 Max: 1372.72
Current: 492.01
492.01
1372.72
Days Sales Outstanding 67.34
SUPN's Days Sales Outstanding is ranked higher than
57% of the 628 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.32 vs. SUPN: 67.34 )
Ranked among companies with meaningful Days Sales Outstanding only.
SUPN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 2.71  Med: 68.02 Max: 16387.12
Current: 67.34
2.71
16387.12
Days Payable 89.02
SUPN's Days Payable is ranked higher than
64% of the 574 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.12 vs. SUPN: 89.02 )
Ranked among companies with meaningful Days Payable only.
SUPN' s Days Payable Range Over the Past 10 Years
Min: 89.02  Med: 186.94 Max: 1038.8
Current: 89.02
89.02
1038.8

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -17.00
SUPN's 3-Year Average Share Buyback Ratio is ranked lower than
80% of the 436 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.40 vs. SUPN: -17.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SUPN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -199.2  Med: -17 Max: 0
Current: -17
-199.2
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 47.55
SUPN's Price-to-Net-Current-Asset-Value is ranked lower than
93% of the 542 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. SUPN: 47.55 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
SUPN' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 3.98  Med: 15.3 Max: 122.18
Current: 47.55
3.98
122.18
Price-to-Tangible-Book 7.90
SUPN's Price-to-Tangible-Book is ranked lower than
78% of the 747 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.65 vs. SUPN: 7.90 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
SUPN' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.86  Med: 7.67 Max: 19.49
Current: 7.9
3.86
19.49
Price-to-Median-PS-Value 0.95
SUPN's Price-to-Median-PS-Value is ranked higher than
63% of the 703 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.13 vs. SUPN: 0.95 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
SUPN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.54  Med: 1.08 Max: 11.48
Current: 0.95
0.54
11.48
Price-to-Graham-Number 2.38
SUPN's Price-to-Graham-Number is ranked lower than
55% of the 443 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.25 vs. SUPN: 2.38 )
Ranked among companies with meaningful Price-to-Graham-Number only.
SUPN' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 2.33  Med: 4.1 Max: 8.71
Current: 2.38
2.33
8.71
Earnings Yield (Greenblatt) % 3.91
SUPN's Earnings Yield (Greenblatt) % is ranked higher than
57% of the 835 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. SUPN: 3.91 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
SUPN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1  Med: 3 Max: 5.5
Current: 3.91
1
5.5

More Statistics

Revenue (TTM) (Mil) $196.3
EPS (TTM) $ 1.57
Beta2.30
Short Percentage of Float5.50%
52-Week Range $12.15 - 27.95
Shares Outstanding (Mil)50.12

Analyst Estimate

Dec16
Revenue (Mil $)
EPS ($) 0.97
EPS without NRI ($) 0.97
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for SUPN

Headlines

Articles On GuruFocus.com
Robert Bruce new Buys Feb 16 2015 
Third Quarter Was Robert Bruce's Busiest in 2014 Nov 21 2014 
Supernus Pharmaceuticals Reports Insider Buys Mar 26 2013 

More From Other Websites
SUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Feb 15 2017
Supernus to Host Fourth Quarter and Full Year 2016 Earnings Conference Call Feb 13 2017
SUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Feb 10 2017
Supernus Announces Issuance of Eighth U.S. Patent Protecting Trokendi XR® Feb 08 2017
Supernus Announces Issuance of Seventh U.S. Patent Protecting Trokendi XR® Jan 30 2017
SUPERNUS PHARMACEUTICALS INC Financials Jan 26 2017
Greater Washington's fastest-growing company forced to lower earnings, income for two years Jan 24 2017
Company News for January 24, 2017 Jan 24 2017
SUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Jan 23 2017
Supernus Pharmaceuticals, Inc. – Value Analysis (NASDAQ:SUPN) : January 23, 2017 Jan 23 2017
Supernus Files Form 10-Q for Third Quarter 2016 and Is Now Current with All Financial Filings Jan 23 2017
SUPERNUS PHARMACEUTICALS INC Files SEC form 10-Q/A, Quarterly Report Jan 23 2017
Supernus misses 3Q revenue forecasts Jan 20 2017
Supernus misses 3Q revenue forecasts Jan 20 2017
SUPERNUS PHARMACEUTICALS INC Files SEC form 10-Q/A, Quarterly Report Jan 20 2017
Supernus Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : SUPN-US :... Jan 20 2017
Q4 Earnings Preview: Stocks Expecting 50% Or Higher Growth Jan 15 2017
SUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 06 2017
Supernus to Present at the 2017 J.P. Morgan Healthcare Conference Jan 03 2017
4 stocks to watch Dec 21 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)